Physician profile
Mark Hatfield
NPI 1932832649
$977.75
in general payments reported to CMS, 2019-2025
14 companies · $99.30 in 2025
The $99.30 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $91.33 · 2023: $505 · 2024: $282 · 2025: $99.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $218.86 | 2022-2024 | |
| Baxter Healthcare | $167.45 | 2024 | Hillrom - Monarch Airway Clearance System |
| Dexcom, INC. | $145.29 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.89 | 2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.26 | 2022-2023 | Lifevest |
| Pfizer INC. | $65.69 | 2023 | |
| Lilly USA, LLC | $35.32 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $34.22 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $32.00 | 2022-2023 | Recarbrio, Dificid, Zerbaxa |
| Lantheus Medical Imaging, INC. | $25.42 | 2023 | Definity |
| Atricure, INC. | $25.19 | 2023 | |
| United Therapeutics Corporation | $18.82 | 2024 | Tyvaso |
| Kiniksa Pharmaceuticals, LTD. | $14.59 | 2023 | Arcalyst |
| Lemaitre Vascular, INC. | $10.75 | 2023 | Artegraft Vascular Graft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hatfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.